Delivery Order SPE2DB22D3501-SPE2DB26FTK47
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,862.79 to AmerisourceBergen Drug Corp for Zeposia 0.92 mg capsules (30-count) on July 24, 2025, with an ultimate completion date of August 14, 2025. The contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs. This delivery order...
- The Defense Logistics Agency awarded a $13,862.79 delivery order to AmerisourceBergen Drug Corp for Zeposia 0.92 mg capsules (30-count units) on September 10, 2025, with an ultimate completion date of October 1, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's substantial...
- The Defense Logistics Agency awarded a delivery order valued at $13,862.79 to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count units) under a firm fixed-price contract. The award was issued on July 29, 2025, with an ultimate completion date of August 19, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp will perform the delivery from its corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $13,862.79 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units). This is a firm fixed-price contract with an ultimate completion date of August 20, 2025, and represents a non-competitive set-aside delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be performed and delivered from the company's Conshohocken,...
- The Defense Logistics Agency awarded a $41,588.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zeposia 0.92 mg capsules (30-count units) on September 25, 2025, with completion required by October 17, 2025. This non-competitive delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $4,620.94 to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count package) under a firm fixed price arrangement. This non-competitive, non-set-aside delivery order was awarded on October 28, 2025, with an ultimate completion date of November 19, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, which serves as the company's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Zeposia 0.92 mg capsules (30-count) with a ceiling value of $13,862.79. This firm fixed-price delivery order represents a non-competitive award and is scheduled for completion by August 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a leading pharmaceutical distributor, AmerisourceBergen maintains a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for Zeposia 0.92 mg capsules (30-count units) under a firm fixed-price contract valued at $13,862.79. This non-set-aside competitive award, with an ultimate completion date of August 18, 2025, will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zeposia 0.92 mg capsules (30-count) under a firm fixed-price contract with a ceiling value of $4,620.93. The award was made on September 15, 2025, with an ultimate completion date of October 6, 2025. This non-set-aside award represents a competitive procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units) with a contract value of $4,620.93. This non-competitive delivery order utilizes firm fixed pricing and is scheduled for completion by September 25, 2025. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB26FTK47Delivery Order
The Defense Logistics Agency awarded a $13,862.82 firm fixed price delivery order to AmerisourceBergen Drug Corp on November 5, 2025, for the supply of Zeposia 0.92 mg capsules (30-count units). This non-set-aside competitive award is scheduled for completion by November 28, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, fulfills this delivery order under its broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. AmerisourceBergen Drug Corp's extensive pharmaceutical supply portfolio supports military healthcare systems, the Defense Health Agency, and other federal medical programs worldwide. The company demonstrates proven capability in delivering a comprehensive range of medications and medical supplies through consistent competitively awarded contracts with the DLA Medical Supply Chain. Zeposia, used in the treatment of multiple sclerosis and ulcerative colitis, represents one of the specialized pharmaceutical products the contractor supplies to support federal healthcare requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.9k | 11/5/25 |